Dr. Wolf on Updated Findings With Capmatinib in METex14-Mutant NSCLC

Dr. Wolf on Updated Findings With Capmatinib in METex14-Mutant NSCLC

Jüergen Wolf, MD, medical director of the Center for Integrated Oncology and professor of Interdisciplinary Translational Oncology at University Hospital of Cologne, discusses data the phase 2 GEOMETRY mono-1 trial with capmatinib (Tabrecta) in patients with METex14-mutated or high MET amplified advanced non–small cell lung cancer. Website: https://www.onclive.com Twitter:   / onclive   Facebook:   / onclive   LinkedIn:   / onclive